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Metronomic chemotherapy refers to the administration of chemotherapy at low, nontoxic doses on a frequent schedule with no
prolonged breaks. The aim of the study is to rationally develop a CPT-11 metronomic regimen in preclinical settings of colon cancer.
In vitro cell proliferation, apoptosis and thrombospondin-1/vascular endothelial growth factor (TSP-1/VEGF) expression analyses were
performed on endothelial (HUVEC, HMVEC-d) and colorectal cancer (HT-29, SW620) cells exposed for 144h to metronomic
concentrations of SN-38, the active metabolite of CPT-11. HT-29 human colorectal cancer xenograft model was used, and tumour
growth, microvessel density and VEGF/TSP-1 quantification was performed in tumours. In vitro and in vivo combination studies with
the tyrosine inhibitor semaxinib were also performed. SN-38 preferentially inhibited endothelial cell proliferation alone and interacted
synergistically with semaxinib; it induced apoptosis and increased the expression and secretion of TSP-1. Metronomic CPT-11 alone
and combined with semaxinib significantly inhibits tumour growth in the absence of toxicity, which was accompanied by decreases in
microvessel density and increases in TSP-1 gene expression in tumour tissues. In vitro results show the antiangiogenic properties of
low-concentration SN-38, suggesting a key role of TSP-1 in this effect. In vivo, the CPT-11 metronomic schedule is effective against
tumour and microvessel growth without toxic effect on mice.
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The interest in exploiting chemotherapeutic drugs for their
antiangiogenic properties in the context of cancer therapy has
been stimulated by a number of preclinical studies, in particular
the pioneering contribution of Folkman and co-workers and that
of the groups of Kerbel and Hanahan (Browder et al, 2000;
Klement et al, 2000; Bocci et al, 2002; Man et al, 2002; Pietras and
Hanahan, 2005) using drugs such as cyclophosphamide, oral
fluoropyrimidines, vinblastine or taxanes at doses much lower
than the maximum-tolerated dose (MTD), administered at close
regular intervals either alone or in combination with targeted
antiangiogenic drugs. The metronomic chemotherapy strategy – a
long-term, low-dose, frequent administration of chemotherapeutic
drugs with no prolonged drug-free breaks (Kerbel and Kamen,
2004) – appears to enhance the efficacy of the antiangiogenic
effects of standard chemotherapy (with lower toxic effects) and
implies that activated vascular endothelial cells (Bocci et al, 2002)
or circulating endothelial progenitors (Bertolini et al, 2003) may be
more sensitive to low or lower doses of various chemotherapeutic
drugs. Besides a direct effect on endothelial cell proliferation,
protracted exposure to low concentrations of several different
anticancer agents, including microtubule inhibitors and alkylating
agents, can cause marked induction, in vitro and in vivo, of gene
and protein expression of thrombospondin-1 (TSP-1), a potent
and endothelial-specific inhibitor of angiogenesis (Sund et al,
2005), suggesting that it could be a key mediator for metronomic
chemotherapy activity (Bocci et al, 2003; Damber et al, 2006;
Hamano et al, 2004).
Despite abundant information about the pharmacology of
irinotecan (CPT-11) (Di Paolo et al, 2006) and its active metabolite
SN-38 on cancer cells using different therapeutic approaches, no
data are currently available about the preclinical effects of
metronomic CPT-11 administration on pathological angiogenesis
and tumour growth. O’Leary et al (1999) have described an
antiangiogenic effect of CPT-11 in a single experimental setting
(using a cornea model of angiogenesis), whereas Kamiyama et al
(2005) reported that SN-38, at cytotoxic standard doses, inhibited
both endothelial cell proliferation and tube formation, decreasing
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sHIF-1a and vascular endothelial growth factor (VEGF) gene
expression in glioma cells under both normoxic and hypoxic
conditions. However, no further preclinical studies have followed
these preliminary reports evaluating possible additional mechan-
isms of drug action.
On the basis of this background, we decided to test, for the first
time, the hypothesis that CPT-11 metronomic regimens can be
effective in preclinical settings of colon cancer treatment;
specifically, we investigated the in vitro and in vivo antiangio-
genic/antitumour activity and the modulation of pro- (VEGF) and
antiangiogenic (TSP-1) factor expression/secretion using low-dose
schedules. Moreover, the effect of the simultaneous combination of
irinotecan or SN-38 with semaxinib was studied both in vitro and
in vivo.
MATERIALS AND METHODS
In vitro studies
Materials, drugs and cell lines Recombinant human epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF) and
VEGF were from PeproTechEC LTD (London, UK). Cell culture
media, MCDB131 and DMEM, were purchased from Gibco BRL
(Paisley, UK), quantitative real-time PCR (QRT-PCR) reagents
were from Applied Biosystems (Foster City, CA, USA), supple-
ments and all other chemicals not listed in this section were
obtained from Sigma Chemical Co. (St Louis, MO, USA).
SN-38 was a generous gift from Pfizer (Groton, CT, USA) and
dissolved in a stock solution of 10mM in 100% DMSO for in vitro
studies. CPT-11 (Pfizer) was purchased from the University
hospital pharmacy (Ospedale S Chiara, Pisa, Italy) and recon-
stituted as per the manufacturer’s instructions to a stock
concentration of 20mgml
 1 by the addition of sterile saline for
in vivo studies.
Semaxinib (SU5416) was purchased from Sigma Chemical Co.
and was dissolved in 100% DMSO for in vitro use and in a solution
of 99% PEG-300 (w/v) and 1% Tween 80 for in vivo studies (Bocci
et al, 2004a).
Human umbilical vein endothelial cells (HUVEC) and the
human dermal microvascular endothelial cells (HMVEC-d; Clo-
netics, San Diego, CA, USA) were maintained in MCDB131 culture
medium supplemented with 10% heat-inactivated FBS, L-glutamine
2m M, heparin 10Uml
 1, EGF 10ngml
 1 and bFGF 5ngml
 1. The
human colon tumour cell lines HT-29 and SW620 (ATCC,
Manassas, MA, USA) were maintained in 10% FBS DMEM medium
supplemented with L-glutamine 2mM.
Cell proliferation assay and apoptosis measurements Human
umbilical vein endothelial cells, HMVEC-d, HT29 and SW620 cells
were plated in 24-well sterile plastic plates (1% gelatin-coated for
the endothelial cells) and treated continuously for 144h (1 10
3
and 0.5 10
3 cells per well of normal or cancer cells, respectively,
in 1ml of medium) with various concentrations of SN-38
(1–100000pM) adding fresh solutions with new medium every
24h (Bocci et al, 2002). Furthermore, to determine a time-
dependent effect on endothelial cell proliferation, HMVEC-d cells
were exposed for 72h to SN-38 (1–100000pM). At the end of the
experiments, cells were harvested with trypsin/EDTA and viable
cells counted with a haemocytometre. Cell viability was assessed by
trypan blue dye exclusion (Bocci et al, 2005). The data are
presented as the percentage of the vehicle-treated cells. The
concentration of drug that reduced cell proliferation by 50% (IC50)
vs controls was calculated by nonlinear regression fit of the mean
values of the data obtained in triplicate experiments (at least nine
wells for each concentration).
To quantify the degree of apoptosis induced by the drug
treatments, HMVEC-d, HUVEC, HT29 and SW620 cells were
continuously treated for 144h with SN-38 at a concentration
corresponding to the experimental IC50 of cell proliferation
(15, 200, 1500 and 650pM, respectively) or vehicle alone. At the
end of the incubation, cells were washed twice with PBS and fixed
in 4% buffered paraformaldehyde for 15min. Cells were resus-
pended and incubated for an additional 15min in a solution
containing 8mgml
 1 bisbenzimide HCl (Hsueh et al, 2000). Cells
were spotted on glass slides and were examined by fluorescence
microscopy (Leica, Wetzlar, Germany). A total of 100 cells from
nine randomly chosen microscopic fields were counted, and the
percentage of cells displaying chromatin condensation and nuclear
fragmentation relative to the total number of counted cells
(apoptotic index) was calculated.
In vitro assessment of synergism between semaxinib and SN-38 on
endothelial cells Semaxinib combined with SN-38 was explored
on HMVEC-d cells with the simultaneous continuous exposure of
semaxinib (0.01–100mM) plus SN-38 (1–10000pM) for 144h at a
fixed molar concentration ratio of 10000:1. To evaluate the level
of interaction (synergistic, additive or antagonist) between SN-38
and semaxinib, the method proposed by Chou (2006) was
followed. Briefly, synergism or antagonism for semaxinib plus
SN-38 was calculated on the basis of the multiple drug–effect
equation, and quantitated by the combination index (CI), where
CIo1, CI¼1 and CI41 indicate synergism, additive effect and
antagonism, respectively. On the basis of the classic isobologram
for mutually exclusive effects, the CI value was calculated as:
CI ¼½ ð DÞ1=ðDXÞ1 þ½ ð DÞ2=ðDXÞ2 
At the 50% inhibition level, (Dx)1 and (Dx)2 are the concentrations
of semaxinib and SN-38, respectively that induce a 50% inhibition
of cell growth; (D)1 and (D)2 are the concentrations of semaxinib
and SN-38 in combination, which also inhibits cell growth by 50%
(isoeffective as compared with the single drugs alone).
Real-time PCR analysis of human VEGF and TSP-1 gene expression
on tumour and endothelial cells To evaluate the expression of the
human VEGF and TSP-1 genes, 2 10
4 HMVEC-d, HUVEC, HT29
and SW620 cells were grown in their respective media and treated
with SN-38 at a concentration corresponding to the experimental
IC50 of cell proliferation (15, 200, 1500 and 650pM, respectively)
and at a lower and inactive dose (1, 10, 10 and 10pM, respectively)
or with vehicle alone for 144h. Briefly, RNA (1mg) was reverse
transcribed as previously described (Bocci et al, 2005), the
resulting cDNA was diluted (2:3) and then amplified by QRT-
PCR with the Applied Biosystems 7900HT sequence detection
system. Vascular endothelial growth factor and TSP-1 validated
primers were purchased from Applied Biosystems (Assay ID
Hs00170236_m1 and Hs00173626_m1, respectively). The PCR
thermal cycling conditions and optimisation of primer concentra-
tions were followed as per the manufacturer’s instructions.
Amplifications were normalised to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and the quantitation of gene expression
was performed using the DDCt calculation, where Ct is the
threshold cycle; the amount of target, normalised to the
endogenous control and relative to the calibrator (vehicle-treated
control cells), is given as 2
 DDCt.
Human VEGF and TSP-1 detection in conditioned media by ELISA
and EIA Human dermal microvascular endothelial cells, HUVEC,
HT29 and SW620 cells were grown in their respective media and
treated with SN-38 at a concentration corresponding to the
experimental IC50 of cell proliferation (15, 200, 1500 and 650pM,
respectively) and at a lower and inactive concentration (1, 10, 10
and 10pM, respectively) or with vehicle alone for 144h.
Furthermore, to determine a time-dependent effect on endothelial
cell secretion, HMVEC-d cells were exposed for 72h to the SN-38
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sexperimental IC50 of cell proliferation (13nM). To measure
secreted VEGF and TSP-1, at the end of the experiment the
medium of each well was discarded and replaced with serum-free
medium for 4h. Each sample was then assayed for human VEGF
and TSP-1 concentrations by the ELISA Kit Quantikine (R&D
Systems, Minneapolis, MN, USA) and by the ChemiKine Human
TSP-1 EIA Kit (Chemicon, Temecula, CA, USA), respectively, and
normalised by total protein concentration. The optical density was
determined using the microplate reader Multiskan Spectrum
(Thermo Labsystems, Milan, Italy) set to 450nm (with a
wavelength correction set to 540nm) for the VEGF kit and to
490nm for TSP-1 kit. All experiments were repeated, indepen-
dently, six times with at least nine samples for each concentration.
Akt (pThr
308) ELISA assay To detect the phosphorylation of Akt
in endothelial cells after a short period of time (72h), HMVEC-d
cells were treated with SN-38 at a concentration corresponding to
the experimental IC50 of cell proliferation (13nM) or with vehicle
alone for 72h. To measure pAkt, at the end of the experiment, the
cells were harvested and immediately frozen with liquid nitrogen.
Each sample was then assayed for human pAkt (pThr
308)
concentrations by the ELISA Kit PhosphoDetect Akt (pThr
308)
(Calbiochem, San Diego, CA, USA) and normalised by total protein
concentration. The optical density was determined using the
microplate reader Multiskan Spectrum set to 450nm. The results
were expressed as pAKT unit per mg of total protein. All
experiments were repeated, independently, six times with at least
nine samples for each concentration.
In vivo studies
Animals CD nu/nu male mice, weighing 20–25g, were supplied
by Charles River (Milan, Italy) and were allowed unrestricted
access to food and tap water. Housing and all procedures involving
animals were performed according to the protocol approved by
the Academic Committee for the animal experimentation of the
University of Pisa, in accordance with the European Community
Council Directive 86–609, recognised by the Italian government,
on animal welfare. Each experiment employed the minimum
number of mice needed to obtain statistically meaningful results.
HT-29 xenografts in nu/nu mice and drug treatments HT-29 cell
viability was assessed by trypan blue dye exclusion, and on day 0,
1.3 10
6±5% cells per mouse were inoculated subcutaneously
(s.c.) between the scapulae in 0.2ml per mouse of culture medium
without FBS. Animal weights were monitored and upon appear-
ance of a subcutaneous mass, tumour dimensions were measured
every 2 days in two perpendicular directions using callipers.
Tumour volume (mm
3) was defined as [(w1 w2 w2) (p/6)],
where w1 and w2 were the largest and the smallest tumour
diameters (mm), respectively (Bocci et al, 2004b). The mice were
randomised into groups of six animals. To treat an established
tumour (B35mm
3), from day 15 after cell inoculation, CPT-11
was administered i.p. as follows: (1) CPT-11 at the MTD of
100mgkg
 1 five times at 7-day intervals (Allegrini et al, 2004); (2)
metronomic CPT-11 every day at the dose of 4mgkg
 1 for 50 days
(a 72% decrease vs MTD dose); (3) a sequential treatment of an
initial (‘up-front’) single dose of CPT-11 100mgkg
 1 followed by
metronomic CPT-11 4mgkg
 1 every day for 49 days. The control
group was injected i.p. with vehicle alone (saline solution). The
experimental period ended 65 days after the inoculation of tumour
cells whereas control mice were killed by an anaesthetic overdose
when the tumour volume reached a mean value of 3200mm
3.
To establish the antitumour activity of metronomic CPT-11 and
semaxinib combination in vivo, an additional experiment was
performed. On day 15, from HT-29 cell inoculum, metronomic
CPT-11 schedules and their simultaneous combinations with
semaxinib were administered i.p. as follows: (1) metronomic
CPT-11 every day at the dose of 4mgkg
 1 for 33 days; (2) an initial
single dose of CPT-11 100mgkg
 1 followed by metronomic CPT-
114mgkg
 1 every day for 32 days; (3) combination treatment of
CPT-11 4mgkg
 1 every day and semaxinib 10mgkg
 1 twice
weekly; (4) combination treatment of an initial single dose of
CPT-11 100mgkg
 1 followed by metronomic CPT-11 4mgkg
 1
every day and semaxinib 10mgkg
 1 twice weekly. The control
group was injected i.p. with vehicle alone (saline solution and PEG-
300/Tween 80). Animal weights were monitored as described
above. Drug efficacy was based on percentage of the average
treated-tumour volume divided by the average vehicle-control-
tumour volume (% T/C) (Tahir et al, 2003).
Immunohistochemistry, microvessel density and real-time RT-PCR
on HT-29 tumour tissue samples After surgical resection, tumour
tissue samples from all the different treatment groups were split
into two aliquots, one fixed in 10% phosphate-buffered formalde-
hyde for 12–24h and embedded in paraffin for histology and
immunohistochemistry, the other immediately frozen in liquid
nitrogen for the analysis of human VEGF and TSP-1 gene
expression by real-time RT-PCR.
Five-micrometre sections were stained with haematoxylin–
eosin for histological analysis. Adjacent sections were cut for
immunohistochemistry as previously described (Viacava et al,
2004) using the following primary antibodies: rat anti-mouse CD31
(dilution, 1:100; PharMingen, San Diego, CA, USA) for evaluation
of microvascular density and the rabbit anti-human VEGF-A to
screen VEGF as a tumour cell-associated angiogenic factor
(Oncogene Research Products, Cambridge, MA, USA; dilution
1:100). Negative controls were obtained by replacing the primary
antibody with nonimmune serum.
Cytoplasmic staining was scored positive for VEGF-A. The
degree of positivity was evaluated by calculating the percentage of
immunoreactive cells on a minimum of 500 cells (Viacava et al,
2004). To calculate microvessel density, three most vascularised
areas of the tumour (‘hot spots’) were selected and mean values
obtained by counting vessels. A single microvessel was defined as a
discrete cluster of cells positive for CD31 staining, with no
requirement for the presence of a lumen. Microvessel counts were
performed at  200 ( 20 objective lens and  10 ocular lens;
0.74mm
2 per field). All parameters were determined indepen-
dently by three expert pathologists (PV, AGN and GF), and
discordant cases were solved by simultaneous review.
The frozen HT-29 xenografts were collected and total RNA was
isolated from the tissues using the Trizol Kit (Gibco). Human
VEGF and TSP-1 gene expression in tumour samples was
performed by real-time PCR as described above.
Statistical analysis The analysis by ANOVA, followed by the
Student–Newman–Keuls test, was used to assess the statistical
differences of data in vitro and in vivo. P-values lower than 0.05
were considered significant. Statistical analyses were performed
using the GraphPad Prism software package version 4.0 (GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
In vitro studies
Protracted low-dose treatment with SN-38 preferentially inhibits
endothelial cell proliferation and induces apoptosis The 144-h
SN-38 exposure inhibited the cell growth of HMVEC-d and
HUVEC in a concentration-dependent manner (Figure 1A),
and the calculated IC50 values were 0.014±0.002 and
0.2±0.029nM, respectively; in contrast, SN-38 did not significantly
affect the proliferation of SW620 and HT-29 cell line at low
concentrations, showing much higher IC50 values (0.64±0.014 and
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s1.5±0.05nM, respectively; Figure 1A). Furthermore, the 72-h
treatment showed a lower antiproliferative activity of SN-38 on
microvascular endothelial cells (IC50 13.3±4.71nM), underlying a
time-dependent effect (Figure 1B).
As shown in Figure 1C, after 144h of treatment at their
respective SN-38 IC50s, a significant percentage of apoptotic
endothelial cells in the treated samples were found (e.g. 20±0.5
vs 2.5±0.3% of control HMVEC-d apoptotic cells) when compared
to controls. These apoptotic percentages were similar to those
obtained and expected, when treating cancer cells at higher doses
such as their IC50s (Figure 1D).
Simultaneous and continuous exposure of HMVEC-d cells to
low concentrations of SN-38 and semaxinib for 144h showed
strong and moderate synergism (CI o1) at effect levels of 25 and
50% inhibition of cell proliferation, respectively, but an antag-
onistic effect for fraction affected higher than 65% (Figure 2A).
Figure 2B shows a representative isobologram of HMVEC-d cells
exposed to low concentrations of SN-38 and semaxinib for 144h
with simultaneous and continuous exposure schedule of treatment.
The position of the data point on the left of the line connecting the
IC50 values of SN-38 and semaxinib indicates synergism
(Figure 2B).
Protracted low-dose treatment with SN-38 modulates expression
and secretion of TSP-1 and VEGF in endothelial and cancer
cells SN-38 significantly increased TSP-1 expression in both
endothelial cell populations tested at their respective IC50s and
lower doses (Po0.05; Figure 3A and B). In particular, a 144-h SN-
38 exposure at its IC50 levels resulted in a significant increase in
TSP-1 expression in HMVEC-d cells (2.49±0.12 vs 1.0 of control
expression; Figure 3A). Similar results were observed for HUVEC
cells, in which TSP-1 expression was increased by SN-38 up to
1.44±0.05 vs 1.0 of controls (Figure 3B). In contrast, TSP-1
expression in HT-29 and SW620 cancer cells was stable (Figure 3C)
or decreased at low SN-38 concentrations (Figure 3D), whereas at
IC50 SN-38 levels, it was significantly decreased when compared to
controls (Figure 3C and D). Moreover, SN-38 exposure positively
modulated TSP-1 protein secretion (normalised for total protein)
in both the endothelial cell populations tested (Figure 3A and B),
confirming the data obtained at the mRNA level. In particular,
TSP-1 secretion was significantly increased up to 845±94 and
775±74% in HMVEC-d and HUVEC cells vs 100% of controls,
respectively, at the IC50 SN-38 concentrations (Figure 3A and B).
Interestingly, results obtained with cancer cell cultures revealed
that at SN-38 concentrations corresponding to their IC50s and at
HT-29, IC50=1.5±0.05 nM
SW620, IC50=0.64±0.014 nM
HMVEC-d, IC50=0.014±0.002 nM
HUVEC, IC50=0.2±0.029 nM
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Figure 1 Effect of low-dose SN-38, the active metabolite of CPT-11, on in vitro cell proliferation (A and B). The antiproliferative effects of the drug were
studied using prolonged continuous exposures (144h) on HUVEC, HMVEC-d, HT-29 and SW620 cell lines (A) and shorter ones (72h) on HMVEC-d cells
(B). Symbols and bars, mean values±s.e., respectively. *Po0.05 vs vehicle-treated controls. IC50, the concentration of drug that reduced cell proliferation
by 50%. Pro-apoptotic effects of (C) SN-38 on proliferating endothelial cells treated at their experimental IC50s (lower concentrations) for 144h and (D)
SN-38 on proliferating colorectal cancer cells treated at their experimental IC50s (higher concentrations) for 144h. Columns and bars, mean values
±s.e., respectively. *Po0.05 vs vehicle-treated controls.
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slower exposures, secreted TSP-1 was unchanged (Figure 3C) in
HT-29 cells or significantly reduced (Figure 3D) up to 61.5±20 vs
100% of controls in SW620 cells.
The results of VEGF gene expression and protein secretion
analysis showed a differential response among endothelial cell
lines and colorectal cancer cells after 144-h SN-38 treatments. SN-
38, at its IC50 levels, significantly increased VEGF expression both
in HMVEC-d cells (1.34±0.08 vs 1.0 of control expression;
Figure 3E) and HUVECs (1.43±0.04 vs 1.0 of control expression;
Figure 3F); only a minimal and not significant enhancement of
VEGF expression was observed in HT-29 cells (Figure 3G) whereas
there was a significant decrease in VEGF mRNA in SW620 cells
(0.59±0.07 vs 1.0 of control expression; Figure 3H). Although very
low secreted levels of VEGF were measured (normalised for total
protein), significant increments were observed at a SN-38
concentration corresponding to IC50 levels in both HMVEC-d
and HUVEC cell lines (293±20 and 369±8.5 vs 100% of control,
respectively; Figure 3E and F). On the contrary, VEGF secretion
significantly decreased in both HT-29 cells (Figure 3G) and SW620
cells (Figure 3H) at their respective IC50 concentrations.
Interestingly, shorter periods of exposure to SN-38 (72h) at
concentrations that determined a 50% of inhibition of endothelial
cell proliferation showed a significant increase of secreted TSP-1
(Po0.05) in conditioned media and a weak decrease in VEGF
(P40.05) (Figure 4A). Moreover, at the same SN-38 dose, the
phosphorylation of Akt at Thr
308 resulted in significant inhibition
in HMVEC-d cells (Figure 4B).
In vivo studies
Metronomic CPT-11 significantly inhibits HT-29 tumour growth in
absence of toxicity HT-29 cells injected s.c. in CD nu/nu mice
grew quite rapidly, and tumour masses became detectable 10 days
after xenotransplantation. Tumours in control animals showed a
progressive enlargement in their dimensions and an exponential
growth after B20 days; a mean volume of B3200mm
3 was
reached at day 43 when the animals of the control group were
killed (Figure 5A). Both MTD CPT-11 (100mgkg
 1 every week)
and metronomic CPT-11 (4mgkg
 1 every day) were able to inhibit
tumour growth, although to a different extent, and their
therapeutic effect became significant starting on the eighth and
the eighteenth day, respectively after the beginning of treatments
as compared to controls (Figure 5A). The MTD schedule was
effective, as expected, immediately, whereas the metronomic
treatment effect was delayed; however, the toxicity profiles were
very different between the two treatments (see below). It is
noteworthy that in the group of animals receiving the initial single
high CPT-11 dose followed by a maintenance therapy with
metronomic CPT-11 until the end of the study, the reduction in
tumour growth was significant by day 8 compared to controls
(Figure 5A) and that the tumour growth curve showed a decrease
during the 50-day schedule, significantly diverging from that of
controls (e.g. at day 43, 383±181 vs 3172±263mm
3; Po0.05),
comparable to CPT-11 MTD-treated animals, with a better
response over the last 10 days of the experiment (Figure 5A).
Figure 5B shows the toxicity profiles of the three different
schedules. The metronomic CPT-11 treatment was favourable and
acceptable with no loss of weight throughout the course of the
treatment (Figure 5B) whereas the MTD CPT-11 caused a severe
loss of weight that necessitated veterinary assistance with an
immediate fluid therapy (0.9% saline, 40–80mlkg
 1 s.c. every
24h) to rescue the animals. The nadir of body weight loss was
observed in the week following the first injection and the mean
body weight of mice treated with doses of 100mgkg
 1 had
returned to pretreatment values after 15 days with a continued
supportive fluid therapy for the duration of the treatment
(Figure 5B). However, mice treated with a single initial dose of
100mgkg
 1 and metronomic CPT-11 maintenance therapy
recovered faster and did not require any additional fluid therapy
until the end of the study (Figure 5B). Moreover, it is noteworthy
that the MTD-treated animals never reached body weights similar
to those treated with metronomic CPT-11 schedules.
Metronomic CPT-11 significantly decreases microvessel density and
modulates VEGF and TSP-1 gene expression in HT-29 tumour
tissues The s.c. injection of HT-29 colorectal cancer cells
produced a tumour, the histological picture of which, after
staining with haematoxylin and eosin, was consistent with
colorectal adenocarcinoma (data not shown). A well-defined
CD-31 immunoreactivity was localised in endothelial cells inside
the control tumour mass (Figure 6A). Representative microscopic
pictures showed a reduction of microvessels in the MTD CPT-11-
treated tumours (Figure 6C) whereas a clearly dramatic decrease of
vessels in metronomic CPT-11-treated tumour samples was
detected (Figure 6E and G). On the contrary, while control tumour
xenografts showed a diffuse, strong and easily detectable
immunoreactivity to the anti-VEGF antibody within cancer cells
(Figure 6B), VEGF immunostaining weakly changed in MTD-
treated samples (Figure 6D) and remained unaltered in the
metronomic therapy-treated ones (Figure 6F and H).
To quantify the observed differences among immunoreactivity
of tissue samples of different animal groups, slides were analysed
for vessel count in tumour sections stained with an antibody to
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sCD31. Compared with the control treatment, MTD CPT-11
treatment resulted in a significant decrease in mean vessel count
(25±2.1 vs 52.4±6.2 vessels per mm
2 of controls; Po0.05;
Figure 7A). Furthermore, both metronomic treatments (4mgkg
 1
daily and the one with the initial single 100mgkg
 1 dose followed
by metronomic maintenance) resulted in a massive and significant
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Figure 3 Thrombospondin-1 (TSP-1) gene expression and secretion in HMVEC-d (A), HUVEC (B), HT-29 (C) and SW620 (D) cells exposed to SN-38
at a concentration corresponding to the experimental IC50 of cell proliferation and at a lower and inactive concentration or with vehicle alone for 144h.
Vascular endothelial growth factor (VEGF) expression and secretion in HMVEC-d (E), HUVEC (F), HT-29 (G) and SW620 (H) cells exposed to the above-
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sreduction in mean vessel count (12.3±2.4 and 8.4±2.5 vs
52.4±6.2 vessels per mm
2 of controls, respectively; Po0.05),
although there was no statistical difference between them
(Figure 7A). The quantification of cancer cell VEGF immuno-
reactivity confirmed that there was only a weak decrease in
treated groups without reaching a significant difference
(Figure 7A).
Figure 7B showed the modulation of human TSP-1 and VEGF
gene expression in treated tumours compared with vehicle-treated
control tumours. A significant increase in both TSP-1 and VEGF
expression was found in the metronomic CPT-11-treated tumours
(1.95±0.05 and 1.62±0.04 vs 1.0 of control expression; Po0.05)
whereas no significant changes were demonstrated at the MTD
dose (Figure 7B). Interestingly, these results suggested a dis-
crepancy between VEGF gene expression and VEGF protein
synthesis previously shown with immunohistochemistry and
between TSP-1 expression in vitro and in vivo in the HT-29
cancer cell line.
Inhibition of tumour growth in vivo by metronomic irinotecan and
semaxinib A significant in vivo antitumour effect of metronomic
irinotecan was detected with both the adopted schedules (Figure 8);
however, the administration of the initial single higher dose of
irinotecan followed by the low-dose treatment confirmed to be
more effective than the low-dose treatment alone (Figure 8). The
tumour growth inhibition obtained with the combination of
semaxinib 10mgkg
 1 twice weekly and metronomic irinotecan
4mgkg
 1day
 1 was almost superimposable with irinotecan alone
and no statistical differences were noted (Figure 8). On the
contrary, the combination of semaxinib 10mgkg
 1 twice weekly
and the initial single dose of 100mgkg
 1 irinotecan followed by
the 4mgkg
 1day
 1 irinotecan resulted in an almost complete
regression of tumour volumes (T/C value 5.53% at day 47 of the
experiment; Figure 8) and it was significantly different in the last 7
days of treatment from the same metronomic irinotecan schedule
given alone (Figure 8). The toxicity profile was very favourable
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(B) Body weight of HT-29 tumour-bearing control mice and mice treated
with metronomic CPT-11, MTD CPT-11 and the single high dose followed
by the metronomic schedule. MTD CPT-11 caused a severe loss of weight
that required veterinary assistance with an immediate fluid therapy (m; 0.9%
saline, 40–80mlkg
 1 s.c. every 24h) to save the animals. The group of
animal at MTD CPT-11 needed a continued supportive fluid therapy for
the duration of the treatment, whereas mice treated with a single initial
dose of 100mgkg
 1 and metronomic maintenance did not need any
additional fluid therapy until the end of the study. Symbols and bars,
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experiment between single and combination treatments.
DISCUSSION
Our translational study, for the first time, rationally demonstrated
that low-dose metronomic irinotecan is effective in preclinical
settings (in vitro and in vivo), as an antiangiogenic and antitumour
schedule, modulating both TSP-1 and VEGF gene expression and
secretion.
The preferential antiangiogenic and pro-apoptotic activity in
vitro for protracted low concentrations of chemotherapeutic drugs
has been previously demonstrated for 4-hydroperoxycyclopho-
sphamide, taxanes, epothilones and vinblastine (Bocci et al, 2002;
Klement et al, 2002) but is unclear if all or other anticancer drugs
have the same properties. Usually, in vitro experiments involved a
single drug exposure of between 24 and 72h; however, this does
not mirror the in vivo situation when protracted low-dose
metronomic chemotherapy protocols are administered daily. For
this reason, we designed long-term in vitro assays in which human
tumour cells and macrovascular or microvascular endothelial cells
were exposed daily, for up to 6 days, to various low concentrations
of SN-38. Our results are highly suggestive of the presence of the
so-called ‘antiangiogenic window’ (Bocci et al, 2002) when
protracted exposure to low concentrations of SN-38 was used.
Indeed, there was a clear trend showing the effectiveness of SN-38
picomolar concentrations against endothelial cells, but not against
tumour cells. This was the case not only for the inhibition of
proliferation but also for the induction of apoptosis. These
findings may be explained by the fact that in vitro SN-38
A B
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Figure 6 Representative images of immunohistochemistry of mouse
CD31 and human VEGF in HT-29 xenografts in vehicle-treated mice
(control group) (A and B, respectively), in CPT-11 100mgkg
 1 i.p. every
week (MTD schedule) group of mice (C and D, respectively), in
metronomic CPT-11 4mgkg
 1 i.p. daily group (E and F, respectively)
and in the group treated with an initial single dose of CPT-11 100mgkg
 1
i.p. followed by metronomic CPT-11 4mgkg
 1 i.p. daily (G and H,
respectively). Arrowheads, positively stained cells. Magnification,  200.
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Figure 7 (A) Quantification of microvessel density and VEGF positivity
in HT-29 tumour xenografts administered with MTD and metronomic
CPT-11 schedules. (B) Thrombospondin-1 (TSP-1) and VEGF gene
expression in explanted tumour samples from mice treated with MTD
and metronomic CPT-11 schedules. Columns and bars, mean values
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sprotracted treatment induced a significant increase of TSP-1
expression and secretion in the conditioned media of endothelial
cells at effective concentrations (IC50). Moreover, TSP-1 has been
previously described as a mediator of the specific antiangiogenic
effects of this kind of therapy (Bocci et al, 2003; Damber et al,
2006), and also our results implicate this endogenous angiogenesis
inhibitor as a major mediator of the low-concentration SN-38
antiendothelial in vitro effects we studied.
Interestingly, we also observed that SN-38 determined the
significant increase of TSP-1 in conditioned medium of micro-
vascular endothelial cells after 72h of treatment, a change closer to
the beginning of low-concentration therapy, and an inhibition of
phosphorylation of Akt; these two observations may be mechan-
istically linked as demonstrated by Bussolati et al (2006), who
described the modulatory role of Akt on TSP-1 synthesis in
tumour endothelial cells (TEC). Indeed, the inhibition of Akt
activation by administration of PI3K inhibitors significantly
stimulated the synthesis and release of TSP-1 in TEC (Bussolati
et al, 2006), in agreement with previous data by Niu et al (2004),
who have shown that a loss of Akt signalling was related to a
gradual increase in TSP-1 levels in endothelial cells.
Recently, it has been also reported that low doses of cyclopho-
sphamide, cisplatin or docetaxel increase endothelial cell Fas
receptor (Quesada et al, 2005; Yap et al, 2005). Thrombospondin-1
increases the level of Fas ligand on endothelial cells (Volpert et al,
2002; Yap et al, 2005). Moreover, it has been described that SN-38
induces Fas upregulation and caspase 8-mediated apoptosis in
multiple myeloma cells (Catley et al, 2004). Thus, the low-dose SN-
38 may also increase Fas ligand through the increase of TSP-1
secretion and, maybe, the Fas receptor such as other low doses
chemotherapeutic drugs.
Moreover, these data provided our group with the prospect of
exploiting TSP-1 expression or plasma levels as pharmacodynamic
markers for CPT-11 metronomic chemotherapy clinical regimens,
as previously suggested by Kerbel and Kamen (2004). Low
concentrations of SN-38 did not significantly change VEGF
expression in cancer cells; instead, high and antiproliferative
concentrations of SN-38 caused a strong inhibition of VEGF in
colorectal cancer cell lines, suggesting that SN-38-mediated
cytotoxic damage of cancer cells can cause a strong inhibition of
VEGF secretion. Interestingly, these results are similar to those
obtained by Kamiyama et al (2005) in glioma cell lines treated with
high SN-38 concentrations for 24 and 48h (0.1 and 1mM).
To proceed with the development of metronomic CPT-11, the
second step was to establish the antitumour and antiangiogenic
activity of this schedule in vivo. On the basis of our in vitro IC50
data (a decrease of B70% from the lowest tumour cell IC50 to the
highest endothelial IC50) and on data from previously published
studies (Allegrini et al, 2004), we decided to treat animals with an
MTD regimen (100mgkg
 1 weekly), a metronomic schedule
(4mgkg
 1day
 1, i.e., a decreased total weekly dose of B70% vs
the MTD schedule) and with an initial single high dose
immediately followed by the metronomic regimen. The association
of a bolus dose with a metronomic CPT-11 regimen was suggested
by the results of Shaked et al (2005), who showed a superior
antitumour activity combining intermittent high bolus doses
(spaced 3–6 weeks apart) plus continuous low doses of cyclopho-
sphamide in several tumour models, and by the work of Pietras
and Hanahan (2005), who used a ‘chemo-switch’ regimen
consisting of an initial short course of MTD cyclophosphamide,
followed by long-term low-dose oral cyclophosphamide. Metro-
nomic CPT-11 schedule was very well-tolerated, as expected from
the experience with other low-dose chemotherapeutic drugs
(Emmenegger et al, 2004), when compared to the MTD regimen,
which required a continued supportive therapy, and significantly
inhibited both tumour growth and neovascularisation. Moreover,
the results suggested a superior efficacy and potent antitumour
activity of the combined regimen; this enhanced activity was
probably due to a direct effect of the irinotecan bolus dose on both
drug-sensitive tumour cells and proliferating endothelial cells
(Kerbel et al, 2000; Kamiyama et al, 2005) and a prolonged
antiangiogenic effect of the metronomic regimen. Indeed, the
microvessel density in tumour xenografts was markedly decreased
in metronomic schedules when compared to control group and
also to the MTD regimen, although to a lesser extent, confirming
the data recently published by Ji et al (2007), who demonstrated an
antiangiogenic effect of standard doses of CPT-11 in an orthotopic
metastatic human colon cancer model in ND-GFP nude mice. A
possible key role for TSP-1 in mediating some of the metronomic
antiangiogenic effects of CPT-11 in vivo was suggested by the
enhancement of the gene expression of the endogenous inhibitor
in tumour xenografts found only in the low-dose-treated mice,
whereas the VEGF immunohistochemistry analysis revealed no
significant changes.
Further preclinical steps might be explored such as the
combination of a targeted antiangiogenic drug, for example
VEGFR-2 tyrosine kinase inhibitors, with metronomic irinotecan
therapy, as such combinations show much greater antitumour
efficacy compared with metronomic chemotherapy alone or the
antiangiogenic drug alone (Klement et al, 2000; Kerbel and Kamen,
2004; Pietras and Hanahan, 2005). Indeed, to explore this
possibility, we have associated SN-38 and irinotecan, in vitro and
in vivo respectively, with semaxinib, a VEGFR-2 tyrosine kinase
inhibitor. This combination obtained a synergistic effect in vitro
and enhanced the antitumour activity in vivo of the association of
a bolus dose with a metronomic irinotecan regimen. No preclinical
data are currently available on irinotecan and semaxinib
A, initial single dose of CPT-11 100 mg kg–1 + CPT-11 4 mg kg–1 daily
B, initial single dose of CPT-11 100 mg kg–1 + CPT-11 4 mg kg–1 daily 
+ semaxinib 10 mg kg–1 twice weekly
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Figure 8 In vivo effects of the simultaneous combination of metronomic
CPT-11 schedules and semaxinib on HT-29 tumours xenotransplanted in
CD nu/nu mice expressed as % T/C value. Columns, % T/C values. *Po0.05,
initial single dose of CPT-11 100mgkg
 1 followed by metronomic CPT-11
4mgkg
 1 daily combined with semaxinib 10mgkg
 1 twice weekly vs initial
single dose of CPT-11 100mgkg
 1 followed by metronomic CPT-11
4mgkg
 1 daily.
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scombination at standard doses; however, a phase I study of
escalating doses of semaxinib and irinotecan in patients with
advanced colorectal cancer has been recently published, describing
signs of clinical activity without significant toxicity (Hoff et al,
2006). Our data confirmed the preclinical advantage of the
association between an antiangiogenic drug and metronomic
chemotherapy, as also recently shown by Ma and Waxman (2008),
and may improve the possibility to translate a combination
therapy based on metronomic irinotecan and VEGFR tyrosine
kinase inhibitors into the clinics to reduce the toxicity and enhance
the antitumour effects. Indeed, Garcia et al (2008) have recently
reported encouraging phase II trial results of metronomic
cyclophosphamide, administered daily, in combination with
bevacizumab given every 2 weeks, for treatment of recurrent
ovarian cancer.
In conclusion, the clinical development of a promising
irinotecan-based metronomic chemotherapy and of related phar-
macodynamic markers appears possible. The actual meaning of
our results is the development of a rational and less- or
nonempirical strategy for metronomic irinotecan chemotherapy
‘from bench to bed side’. Indeed, our study focused on and
preclinically suggested possible approaches with respect to
addressing the major questions regarding the clinical application
of metronomic chemotherapy that relates to the actual antiangio-
genic activity of the chosen chemotherapeutic drug, the dosing
levels, the frequency of administration, the possible combinations
with other drugs and the pharmacodynamic surrogate markers to
be used. Indeed, based on our experimental data, we could suggest
initiating pilot phase II clinical trials with at least these four
characteristics: (i) an initial CPT-11 high dose followed by a long-
term continuous infusion of irinotecan in colorectal cancer
patients (including patients whose tumours are already resistant
to irinotecan, but who may respond again because of the
antiangiogenic effect of the metronomic schedules); (ii) the CPT-
11 dose level should be reduced at least 70% of the maximum-
tolerated total dose; (iii) the CPT-11 should be combined with a
recommended dose of a VEGFR-2 tyrosine kinase inhibitor to
improve the overall antitumour effects; (iv) the antiangiogenic
activity could be assessed with pharmacodynamic parameters such
as gene expression and plasma levels of TSP-1 and VEGF.
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